The latest report from a group financed and backed by the pharmaceutical industry “continues to misrepresent” the 340B Drug Pricing Program and its “successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive health services,” AHA Executive Vice President Tom Nickels writes today in an AHA Stat blog post. Nickels says the report “attempts to mislead the debate by comparing changes in the ‘charity care’ provided by a small sample size of 160 disproportionate share hospitals (out of 2,448 hospitals) that participate in the 340B program,” and he highlights the many benefits 340B hospitals provide to the patients and communities they serve. "We hope policymakers won’t be diverted by this self-serving report from the important job of finding solutions to bring down the exorbitant cost of many prescription drugs that is threatening the availability of life-saving medications for millions of Americans,” Nickels writes.

Related News Articles

Headline
The House of Representatives last night voted 419-6 to pass legislation (H.R. 748) that would repeal the 40% excise tax on high-value employer-sponsored health…
Headline
The Health Resources and Services Administration today awarded 27 organizations up to $750,000 each to develop new rural residency programs while achieving…
Headline
The Centers for Medicare…
Headline
Drug overdose deaths declined 5.1% in 2018 to about 68,000, according to preliminary data from the Centers for Disease Control and Prevention.
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The House Ways and Means Committee today launched a health task force to better address the needs of residents in rural and underserved communities.